Cardiff Oncology

Q2 FY2026 EarningsQ2 FY26 results beat consensus on top and bottom lines: revenue $104K vs. $62.8K expected, and GAAP EPS -$0.14 vs. -$0.16 expected. Net loss of $9.2M was narrower than the $11.9M consensus, driven primarily by a $5.7M YoY reduction in R&D expenses due to clinical trial completions. Despite the beat, the company issued a 'going concern' warning, noting cash reserves of $34.5M are insufficient for the next 12 months, though a subsequent $10.1M offering in July extends the runway into Q3 2027.